Clinical Study

Circulating Cytokines and Histological Liver Damage in Chronic Hepatitis B Infection

Kittiyod Poovorawan,1 Pisit Tangkijvanich,2 Chintana Chirathaworn,3 Naruemon Wisedopas,4 Sombat Treeprasertsuk,1 Piyawat Komolmit,1 and Yong Poovorawan5

1 Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
2 Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
3 Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
4 Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
5 Department of Pediatrics, Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Correspondence should be addressed to Yong Poovorawan; yong.p@chula.ac.th

Received 29 May 2013; Revised 3 September 2013; Accepted 20 September 2013

Academic Editor: Piero Luigi Almasio

Copyright © 2013 Kittiyod Poovorawan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Each phase of hepatitis B infection stimulates distinct viral kinetics and host immune responses resulting in liver damage and hepatic fibrosis. Our objective has been to correlate host inflammatory immune response including circulating Th1 and Th2 cytokines in patients with chronic hepatitis B infection with liver histopathology. Sixty-four patients with chronic hepatitis B without previous treatment were recruited. The liver histology and histological activity index were assessed for various degrees of necroinflammation and hepatic fibrosis. We determined circulating levels of the Th1 and Th2 cytokines. Forty-six males and 18 females at a median age of 34.5 years were studied. HBeAg was present in 28/64 (43.75%) of the patients. In patients negative for HBeAg, IL-10 and IFN-gamma were significantly correlated with degrees of necroinflammation (\( r = 0.34 \), \( r = 0.38 \), resp.; \( P < 0.05 \)). Moreover, TNF-alpha was significantly correlated with degrees of fibrosis (\( r = 0.35; P < 0.05 \)), and IL-10 and TNF-alpha were significantly correlated with significant fibrosis (\( r = 0.39, r = 0.35, \) resp.; \( P < 0.05 \)). These correlations were found in the HBeAg negative group as opposed to the HBeAg positive group. In HBeAg negative patients, circulating cytokines IL-10 and IFN-gamma were correlated with degrees of necroinflammation, whereas IL-10 and TNF-alpha were correlated with significant fibrosis.

1. Introduction

Chronic hepatitis B infection is a major cause of chronic liver disease worldwide. Each phase of hepatitis B infection stimulates distinct viral kinetics and host immune responses resulting in liver damage and hepatic fibrosis [1]. Vaccine induced immune response in humans has provided excellent long term protection and result decline prevalence of hepatitis B virus (HBV) infection in long term [2, 3]. In contrast to host immune tolerance, only a small proportion of chronic hepatitis B (CHB) patients could clear the infection [4]. Histological damage and risk of HCC in CHB patients depend on various parameters such as duration of infection, coinfection with other hepatitis viruses, and alcohol consumption [5]. Cytokines are known to play a significant role in host immune responses. In chronic hepatitis B patients, the concentration of circulating Th17 cells (producing IL-17) increased with disease progression from CHB (mean, 4.34%) to acute-on-chronic liver failure (mean, 5.62%) patients as compared to healthy controls (mean, 2.42%) [6]. Furthermore, higher serum levels of IL-10 and IL-12 in HBeAg positive patients are correlated with early, spontaneous HBeAg seroconversion [7]. T cells play a major role in the immunopathogenesis associated with chronic hepatitis B. T cells destroy infected hepatocytes and suppress HBV replication [8]. Our objective
has been to correlate host inflammatory immune response including circulating Th1 and Th2 cytokines in patients with chronic hepatitis B infection with the liver histopathology observed.

2. Materials and Methods

A cross-sectional prospective study was conducted on chronic HBV patients who were evaluated for treatment at Chulalongkorn King Memorial Hospital from 2010 to 2012. The research protocol was approved by the Institutional Review Board (IRB number 515/53) of the Faculty of Medicine, Chulalongkorn University. The objective of the study was explained to the patients, and subsequently, written consent was obtained.

2.1. Patients. Sixty-four patients with chronic hepatitis B without previous treatment were recruited. Clinical, demographic, and laboratory data were collected. Patients with evidence of HCV or HIV coinfection, alcoholic liver disease, and chronic liver disease due to other causes and acute viral hepatitis B were excluded from the study.

2.2. Specimen Collection. From January 2010 to January 2012, 64 samples were collected from patients with chronic HBV infection. Samples were collected as clotted blood and sera were separated within 6 hours. All specimens were kept at −70°C until tested.

2.3. Clinical Assessment. Based on their HBeAg status, patients were classified into an HBeAg positive and an HBeAg negative group. Liver biopsy was performed by percutaneous needle biopsy (16-gauge, Menghini). Specimen length of at least 1.5 cm and at least 10 portal tracks is required for an adequate evaluation [9].

Histology and histological activity index (HAI) were graded according to degrees of necroinflammation applying the following score: 0 = no inflammation, 1–4 = minimal inflammation, 5–8 = mild inflammation, 9–12 = moderate inflammation, and 13–18 = marked inflammation as described by Knodell et al. [10]. Hepatic fibrosis was staged on a 5-point scale (F0: no fibrosis; F1: minimal fibrosis; F2: fibrosis with a few septa; F3: numerous bridging fibroses without cirrhosis; F4: cirrhosis or advanced severe fibrosis) as described in the Metavir score. F0–F1 was defined as nonsignificant fibrosis and F2–F4 as significant fibrosis.

2.4. Liver Stiffness Measurement. Transient elastography was performed by a well-trained nurse using FibroScan 502 (Echosens, Paris, France). The median value of 10 validated scores was considered the elastic modulus of the liver, and it was expressed in kilopascals (kPa).

2.5. Laboratory Method. Circulating levels of Th1 cytokines comprising IL-2, IL-12p70, and interferon-gamma (IFN-gamma) and Th2 cytokines including IL-4, IL-5, IL-10, IL-13, and also TNF-alpha and GMCSF were measured by ELISA (Bio-Plex Cytokine Assays). We quantitatively determined the HBsAg titer by ELISA method (Elecsys, Roche Diagnostics, Indianapolis, IN, USA), and the HBV DNA concentration was measured by quantitative real time PCR (The Abbott m2000sp Real Time System).

We determined serum anti-HCV and anti-HIV by enzyme immunoassay (Architect, Abbott Diagnostics, Germany).

2.6. Statistical Analysis. Continuous variables were compared between groups using unpaired t-test and one-way ANOVA. Categorical variables were compared between groups using chi-square/Fisher’s exact test. Pearson’s correlation coefficient was used to describe the correlation between two continuous, normally distributed variables. Spearman’s correlation was used where variables were not normally distributed. All statistical analyses were performed using SPSS version 16.

3. Results

Forty-six males and 18 females at a median age of 34.5 years were studied. HBeAg was present in 28 of 64 (43.75%) patients. In the study population, HBeAg negative patients were older than those positive for HBeAg. HBV DNA, HBsAg titer, and ALT concentrations were significantly higher in the HBeAg positive group. Degrees of hepatic necroinflammation, liver fibrosis, and liver stiffness measured by FibroScan were not significantly different between both groups (Table 1).

Among all patients, cytokine levels were not correlated with ALT, DNA levels, and liver stiffness measurement by FibroScan. The correlation between IL-5 and HBsAg titer was negative (r = −0.239; P < 0.05).

In HBeAg negative patients, inflammatory cytokine IL-5 and IL-12p70 levels were significantly higher than in HBeAg positive patients (0.726 versus 0.508 and 2.17 versus 0.217, resp.; P < 0.05). Other mean serum cytokine levels were not statistically different (Table 2).

In the HBeAg negative group, IL-10 and IFN-gamma were significantly correlated with degrees of necroinflammation (r = 0.336, r = 0.380, resp.; P < 0.05). While other cytokines were not correlated (Figure 1). In the HBeAg positive group, none of the cytokines was correlated with degrees of necroinflammation (Figure 2). After multivariate analysis with baseline characteristic, laboratory data, and other cytokines, IL-10 was the only one parameter which significantly correlated with degrees of necroinflammation (Table 3).

TNF-alpha was significantly correlated with degrees of fibrosis (r = 0.35; P < 0.05), and IL-10 and TNF-alpha were significantly correlated with significant fibrosis in HBeAg negative patients (r = 0.39, r = 0.35, resp.; P < 0.05). After multivariate analysis with baseline characteristic, associated laboratory data and other cytokines, there was no significant correlation between IL-10, TNF-alpha, and significant fibrosis. In the HBeAg positive group, none of the cytokines was correlated with fibrosis.
Figure 1: Correlation between circulating cytokine levels (pg/mL) and degrees of necroinflammation (Knodell histological activity index) in the HBcAg negative group (N = 36). † Spearman’s rank correlation coefficient, * statistically significant.
Figure 2: Correlation between circulating cytokine levels (pg/mL) and degrees of necroinflammation (Knodell histological activity index) in the HBcAg positive group (N = 28). *Spearman's rank correlation coefficient.
Table 1: Comparison of demographic, clinical, and ALT level, histopathology, and liver stiffness characteristics between HBeAg positive and HBeAg negative patients.

|                      | HBeAg positive (n = 28) | HBeAg negative (n = 36) | P value |
|----------------------|-------------------------|-------------------------|---------|
| Age > 40yrs          | 3/28 (10.7%)            | 21/36 (58.3%)           | <0.01   |
| Age (yrs)            | 30.9 ± 7.9              | 42 ± 10.2               | 0.02    |
| Male gender          | 17/28 (60.7%)           | 28/36 (77.8%)           | 0.14    |
| Mean BMI             | 25.1 ± 4.8              | 23.7 ± 3.8              | 0.43    |
| Underlying of DM     | 0                       | 2/36 (5.6%)             | 0.27    |
| ALT > 60 U/L         | 20/28 (71.4%)           | 16/36 (44.4%)           | 0.03    |
| HBV DNA (logIU/mL)   | 7.08 ± 1.39             | 5.34 ± 1.35             | <0.01   |
| HBsAg titer (IU/mL)  | 20380.8 ± 21308         | 5477 ± 7557.3           | <0.01   |
| Knodell HAI ≥ 4      | 17/28 (60.7%)           | 17/36 (47.2%)           | 0.28    |
| Significant fibrosis | 11/28 (39.3%)           | 21/36 (58.3%)           | 0.13    |
| Liver stiffness (Kpa) | 7.13 ± 2.49             | 7.76 ± 3.72             | 0.09    |

* Plus-minus values are means ± SD for all comparisons.

Table 2: Comparison of cytokine levels between HBeAg positive and HBeAg negative patients.

| (pg/mL)   | HBeAg positive (n = 28) | HBeAg negative (n = 36) | P value |
|-----------|-------------------------|-------------------------|---------|
| IL-2      | 0.517 ± 2.37            | 0.726 ± 0.38            | 0.24    |
| IL-4      | 0.79 ± 1.74             | 0.77 ± 0.83             | 0.95    |
| IL-5      | 0.508 ± 0.16            | 0.726 ± 0.38            | <0.01** |
| IL-10     | 0.217 ± 0.35            | 2.607 ± 11.9            | 0.29    |
| IL-12p70  | 0.898 ± 0.60            | 2.17 ± 3.06             | 0.03**  |
| IL-13     | 0.529 ± 0.31            | 0.803 ± 1.18            | 0.24    |
| GMCSF     | 1.131 ± 0.17            | 1.56 ± 1.84             | 0.35    |
| IFN-gamma | 34.8 ± 40.72            | 37.36 ± 25.43           | 0.76    |
| TNF-alpha | 5.446 ± 10.09           | 5.196 ± 2.93            | 0.89    |

* Plus-minus values are means ± SD for all comparisons.
** Statistically significant.

4. Discussion

Chronic hepatitis B infection results in a complex interplay between virus and host immune response. T-cell immune response is correlated with fibrosis and hepatic inflammation in HBV chronic hepatitis and cirrhotic patients [11]. The phase of disease is determined by clinical characteristics of liver inflammation and virus replication in the host. Chronic hepatitis B (CHB) infection progresses through various phases in relation to the host, that is, immune tolerant, immune active, and inactive carrier. The immune response in each phase of disease depends on complex mechanisms. Recent data have demonstrated that even the immune tolerant phase of CHB is not associated with an immune profile of T-cell tolerance [12].

Cytokines contribute to the immune response and have a specific response to each disease [13]. T-helper cytokines in CHB patients and healthy controls were different. For example, serum IL-33 was significantly higher in healthy controls at the baseline but decreased after antiviral treatment [14]. Some data have demonstrated that the circulating cytokine profile in chronic hepatitis B is related to the HBeAg status, virus replication, and stage of liver disease [15, 16].

Inflammatory cytokine IL-5 and IL-12p70 levels were significantly higher in the HBeAg negative group. A previous study has demonstrated that IL-5 as well as IL-4 levels were increased in acute self-limited hepatitis B [17]. IL-12 was found to significantly augment the HBeAg-specific secretion of IFN-gamma in CHB children and, thus, to increase the probability of HBeAg seroconversion in CHB patients [7, 18]. Treatment of CHB patients with a combined regimen of IL-12 and lamivudine enhanced T-cell reactivity to HBV and IFN-gamma production. However, IL-12 did not suppress HBV replication in HBeAg positive patients and did not uphold inhibition of HBV replication after lamivudine withdrawal [19].

Interleukin-10 (IL-10) generally suppresses cellular immune responses by modulating the function of T cells and antigen-presenting cells [20]. In contrast to CHB patients, IL-10 was related to the HBeAg status, virus replication, and liver disease progression [16]. This study confirmed the correlation between IL-10 and histological liver damage in HBeAg negative CHB patients. Furthermore, a recent study has demonstrated that the IL-10 level can also serve as a predictor of HBeAg seroconversion in CHB patients [7].

IFN-gamma and TNF-alpha were thought to be important immune mediators in the host defense against hepatitis B virus (HBV) infection. These cytokines can induce apoptosis in liver cells expressing HBV [21]. TNF-alpha mediates an innate antiviral response that targets the integrity of HBV.
nucleocapsids [22]. IFN-gamma suppresses hepatitis B virus replication and significantly reduces expression of the large HBV surface protein (LHBs) and hepatocytes' microscopical appearance of ground glass [23].

This study has established that circulating cytokines IL-10 and IFN-gamma are correlated with degrees of necroinflammation in HBeAg negative patients, whereas IL-10 and TNF-alpha are correlated with significant fibrosis. These correlations were found in the HBeAg negative group as opposed to the HBeAg positive group. However, further research should be performed to determine the exact roles of each cytokine in liver necroinflammation and fibrogenesis.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Acknowledgments**

This work was supported by the Chulalongkorn University liver Research Unit, The Higher Education Research Promotion and National Research University Project of Thailand (HR1155A-55), Thailand Research Fund (DPP5480002), Office of the Commission on Higher Education, Center of Excellence in Clinical Virology, Chulalongkorn University, CU Centenary Academic Development Project, and Chulalongkorn Hospital. The authors also would like to thank the entire staff of the Center of Excellence in Clinical Virology, Medicine, Biochemistry, Faculty of Medicine, Chulalongkorn University and Hospital, for their assistance in this research. Finally, the authors would like to thank Ms. Petra Hirsch for reviewing the paper.

**Table 3: Multivariate analyses of the association between degrees of necroinflammation and other parameters.**

| Parameters        | Standardized coefficients | $P$ value |
|-------------------|---------------------------|-----------|
| Age               | -0.13                     | 0.51      |
| BMI               | 0.02                      | 0.93      |
| ALT               | 0.38                      | 0.13      |
| HBV DNA           | 0.07                      | 0.82      |
| HBeAg titer       | -0.16                     | 0.6       |
| IL-2              | -0.38                     | 0.19      |
| IL-4              | 0.35                      | 0.51      |
| IL-5              | 0.16                      | 0.66      |
| IL-10             | 0.96                      | 0.04*     |
| IL-12p70          | -1.69                     | 0.06      |
| IL-13             | 0.67                      | 0.16      |
| GMCSF             | -0.70                     | 0.18      |
| IFN-gamma         | 0.27                      | 0.48      |
| TNF-alpha         | 0.76                      | 0.09      |

* Statistically significant.

**References**

[1] D. Ganem and A. M. Prince, "Hepatitis B virus infection—natural history and clinical consequences," *The New England Journal of Medicine*, vol. 350, no. 11, pp. 1118–1129, 2004.

[2] Y. Poovorawan, V. Chongsrisawat, A. Theamboonlers, H. L. Bock, M. Leyssen, and J.-M. Jacquet, "Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand," *Vaccine*, vol. 28, no. 3, pp. 730–736, 2010.

[3] N. Chimparlee, S. Oota, S. Phikulsod, P. Tangkijvanich, and Y. Poovorawan, "Hepatitis B and hepatitis C Virus in Thai blood donors," *Southeast Asian Journal of Tropical Medicine and Public Health*, vol. 42, no. 3, pp. 609–615, 2011.

[4] R. S. Tedder, S. Ijaz, N. Gilbert et al., "Evidence for a dynamic host-parasite relationship in e-negative hepatitis B carriers," *Journal of Medical Virology*, vol. 68, no. 4, pp. 505–512, 2002.

[5] A. S. F. Lok and B. J. McMahon, "Chronic hepatitis B: update 2009," *Hepatology*, vol. 50, no. 3, pp. 661–662, 2009.

[6] J.-Y. Zhang, Z. Zhang, F. Lin et al., "Interleukin-17-producing CD4+ T cells increase with severity of liver damage in patients with chronic hepatitis B," *Hepatology*, vol. 51, no. 1, pp. 81–91, 2010.

[7] J.-F. Wu, T.-C. Wu, C.-H. Chen et al., "Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion," *Gastroenterology*, vol. 138, no. 1, pp. 165–172, 2010.

[8] Y. Shimizu, "T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection," *The World Journal of Gastroenterology*, vol. 18, no. 20, pp. 2443–2451, 2012.

[9] D. C. Rockey, S. H. Caldwell, Z. D. Goodman, R. C. Nelson, and A. D. Smith, "Liver biopsy," *Hepatology*, vol. 49, no. 3, pp. 1017–1044, 2009.

[10] R. G. Knodell, K. G. Ishak, W. C. Black et al., "Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis," *Hepatology*, vol. 1, no. 5, pp. 431–435, 1981.

[11] J.-T. Tang, J.-Y. Fang, W.-Q. Gu, and E.-L. Li, "T cell immune response is correlated with fibrosis and inflammatory activity in hepatitis B cirrhotics," *The World Journal of Gastroenterology*, vol. 12, no. 19, pp. 3015–3019, 2006.

[12] P. Kennedy, E. Sandalova, J. Jo et al., "Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B," *Gastroenterology*, vol. 143, no. 3, pp. 637–645, 2012.

[13] A. Bertolotti, M. M. D’Elios, C. Boni et al., "Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections," *Gastroenterology*, vol. 112, no. 1, pp. 193–199, 1997.

[14] J. Wang, Y. Cai, H. Ji et al., "Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B," *Journal of Interferon & Cytokine Research*, vol. 32, no. 6, pp. 248–253, 2012.

[15] S. Khan, A. Bhargava, N. Pathak, K. K. Maudar, S. Varshney, and P. K. Mishra, "Circulating biomarkers and their possible role in pathogenesis of chronic hepatitis B and C viral infections," *Indian Journal of Clinical Biochemistry*, vol. 26, no. 2, pp. 161–168, 2011.

[16] H. Bozkaya, M. Bozdaiy, R. Turkyilmaz et al., "Circulating IL-2, IL-10 and TNF-α in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease," *Hepato-Gastroenterology*, vol. 47, no. 36, pp. 1675–1679, 2000.
[17] A. Penna, G. del Prete, A. Cavalli et al., “Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B,” *Hepatology*, vol. 25, no. 4, pp. 1022–1027, 1997.

[18] A. Szkaradkiewicz, A. Jopek, and J. Wysocki, “Effects of IL-12 and IL-18 on HBeAg-specific cytokine production by CD4 T lymphocytes of children with chronic hepatitis B infection,” *Antiviral Research*, vol. 66, no. 1, pp. 23–27, 2005.

[19] E. I. Rigopoulou, D. Suri, S. Chokshi et al., “Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity,” *Hepatology*, vol. 42, no. 5, pp. 1028–1036, 2005.

[20] M. Ejrnaes, C. M. Filippi, M. M. Martinic et al., “Resolution of a chronic viral infection after interleukin-10 receptor blockade,” *Journal of Experimental Medicine*, vol. 203, no. 11, pp. 2461–2472, 2006.

[21] H. Shi and S.-H. Guan, “Increased apoptosis in HepG2.2.15 cells with hepatitis B virus expression by synergistic induction of interferon-γ and tumour necrosis factor-α,” *Liver International*, vol. 29, no. 3, pp. 349–355, 2009.

[22] R. Puro and R. J. Schneider, “Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA,” *Journal of Virology*, vol. 81, no. 14, pp. 7351–7362, 2007.

[23] K. Reifenberg, E. Hildt, B. Lecher et al., “IFNγ expression inhibits LHBs storage disease and ground glass hepatocyte appearance, but exacerbates inflammation and apoptosis in HBV surface protein-accumulating transgenic livers,” *Liver International*, vol. 26, no. 8, pp. 986–993, 2006.